Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age… Read more
Market Cap & Net Worth: Emmaus Life Sciences Inc (EMMA)
Emmaus Life Sciences Inc (OTCQB:EMMA) has a market capitalization of $1.19 Million ($1.19 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #36784 globally and #11965 in its home market, demonstrating a -10.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Emmaus Life Sciences Inc's stock price $0.02 by its total outstanding shares 70198263 (70.20 Million).
Emmaus Life Sciences Inc Market Cap History: 2015 to 2025
Emmaus Life Sciences Inc's market capitalization history from 2015 to 2025. Data shows change from $2.53 Billion to $1.19 Million (-57.82% CAGR).
Emmaus Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Emmaus Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
Emmaus Life Sciences Inc's market cap is 0.13 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.53 Billion | $100.10K | -$3.38 Million | 25246.06x | N/A |
| 2016 | $635.29 Million | $85.10K | -$5.94 Million | 7465.27x | N/A |
| 2017 | $1.43 Billion | $128.50K | -$7.11 Million | 11144.32x | N/A |
| 2018 | $308.31 Million | $1.32 Million | -$9.60 Million | 234.37x | N/A |
| 2019 | $138.29 Million | $22.75 Million | -$54.84 Million | 6.08x | N/A |
| 2020 | $86.34 Million | $23.17 Million | $1.35 Million | 3.73x | 63.77x |
| 2021 | $117.23 Million | $20.61 Million | -$15.95 Million | 5.69x | N/A |
| 2022 | $18.27 Million | $18.39 Million | -$10.69 Million | 0.99x | N/A |
| 2023 | $7.03 Million | $29.60 Million | -$3.73 Million | 0.24x | N/A |
| 2024 | $2.10 Million | $16.65 Million | -$6.45 Million | 0.13x | N/A |
Competitor Companies of EMMA by Market Capitalization
Companies near Emmaus Life Sciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Emmaus Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Emmaus Life Sciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Emmaus Life Sciences Inc's market cap moved from $2.53 Billion to $ 1.19 Million, with a yearly change of -57.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.19 Million | -43.14% |
| 2024 | $2.10 Million | -70.13% |
| 2023 | $7.03 Million | -61.54% |
| 2022 | $18.27 Million | -84.41% |
| 2021 | $117.23 Million | +35.77% |
| 2020 | $86.34 Million | -37.56% |
| 2019 | $138.29 Million | -55.15% |
| 2018 | $308.31 Million | -78.47% |
| 2017 | $1.43 Billion | +125.41% |
| 2016 | $635.29 Million | -74.86% |
| 2015 | $2.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Emmaus Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.19 Million USD |
| MoneyControl | $1.19 Million USD |
| MarketWatch | $1.19 Million USD |
| marketcap.company | $1.19 Million USD |
| Reuters | $1.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.